Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Metacrine

Metacrine
2014 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Series B LATEST DEAL TYPE
$22M LATEST DEAL AMOUNT
7 INVESTORS
Description

Provider of biotechnology services intended to develop innovative drug therapeutics for metabolic diseases. The company's biotechnology services specializes in dealing with class of insulin sensitizer having the potential to correct underlying defects in type 2 diabetes with fewer safety issues than existing agents and a compound that works in the intestine, enabling patients to avail two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
  • 12780 El Camino Real
  • Suite 301
  • San Diego, CA 92130
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Metacrine’s full profile, request a free trial.

Metacrine Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 07-Dec-2017 $22M 000.00 0000 Completed Startup
1. Early Stage VC (Series A) 02-Nov-2016 000.00 000.00 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Metacrine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.0 00.0 00 00.0 000
Series A 00,000,000 00.000000 00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Metacrine Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
The Longevity Fund Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Metacrine Executive Team (9)

Name Title Board
Seat
Contact
Info
Ken Song MD President, Board of Director & Chief Executive Officer
Trisha Millican Chief Financial Officer
Ronald Evans Ph.D Co-Founder & Independent Director
Nicholas Smith Ph.D Senior Vice President, Chemistry
Eric Bischoff Vice President, Development and Business Operations

2 Former Executives

You’re viewing 5 of 9 executives. Get the full list »

Metacrine Board Members (6)

Name Representing Role Since Contact
Info
Amir Nashat Ph.D Polaris Partners Board Member 000 0000
Carol Gallagher New Enterprise Associates Board Member 000 0000
Kristina Burow ARCH Venture Partners Board Member 000 0000
Richard Heyman Ph.D Self Executive Chairman & Co-Founder 000 0000
Robert Adelman MD venBio Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »